Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06126497 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
A Phase 2 study, sponsored by Suven Life Sciences Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT06126497: Completed Phase 2 study, sponsored by Suven Life Sciences Limited.
NCT06126497 is a Phase 2 study that has completed, run by Suven Life Sciences Limited. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06126497, a Phase 2 study, has completed, sponsored by Suven Life Sciences Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
Primary Outcome
Participants with at least one Treatment-emergent adverse events (TEAEs) reported during the duration of the study.
Interventions
- DRUG Ropanicant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2024-07-19 |
| Phase | Phase 2 |
What the finished NCT06126497 record still lists
NCT06126497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 1 intervention - of which Ropanicant is the first listed.
NCT06126497 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06126497 about?
NCT06126497 is a clinical study titled "Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients". This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
What is the current status of trial NCT06126497?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2024-02-05. Estimated completion is 2024-07-19.
What interventions are being tested in trial NCT06126497?
The interventions under investigation include: Ropanicant (DRUG).
Who is sponsoring clinical trial NCT06126497?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06126497's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI